3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Lymphoid
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
688
Lymphoma, T-Cell, Cutaneous
116
Keratosis, Actinic
109
Skin Neoplasms
99
Carcinoma, Non-Small-Cell Lung
81
Mycosis Fungoides
79
Neoplasm Metastasis
78
Neoplasms
75
Sezary Syndrome
74
Lymphoma, Non-Hodgkin
72
Leukemia, Lymphocytic, Chronic, B-Cell
65
Lymphoma, Follicular
64
Lymphoma, Large B-Cell, Diffuse
63
Lymphoma, B-Cell, Marginal Zone
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
59
Lymphoma, Mantle-Cell
59
Uveal Melanoma
58
Carcinoma, Renal Cell
58
Carcinoma, Basal Cell
58
Lymphoma, Large-Cell, Immunoblastic
56
Hodgkin Disease
56
Burkitt Lymphoma
55
Lymphoma
52
Lymphoma, Large-Cell, Anaplastic
50
Waldenstrom Macroglobulinemia
44
Multiple Myeloma
44
Lymphoma, Extranodal NK-T-Cell
44
Breast Neoplasms
44
Immunoblastic Lymphadenopathy
43
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
41
Interventions
pembrolizumab
1
GSK-3326595
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Adenoid Cystic
×
Dermatologic
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts